1. MYPP trial studied myo-inositol in pregnancy among PCOS patients.
2. 464 participants were randomized to receive either treatment or placebo.
3. Composite outcomes showed no significant difference, 25% vs. 27%.
4. Gestational diabetes rates were similar, 17% vs. 16%.
5. Moderate adherence noted in both groups.
6. Limitations included differences in baseline characteristics and lower event rates.
7. Follow-up continued through December 2023.
8. Adverse events were similar across groups.

Source: JAMA